Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology Guideline

作者：Sridhar Chaganti, Christopher P. Fox, Bernard Maybury, Cathy Burton, Sally F. Barrington, Tim Illidge, Nagesh Kalakonda, Toby A. Eyre, Pam McKay, Andrea Kühnl, Kate Cwynarski, Andrew Davies · 发表于：British Journal of Haematology · 年份：2025 · DOI：10.1111/bjh.20129 · 被引用次数：7 · 研究领域：Lymphoma Diagnosis and Treatment、Chronic Lymphocytic Leukemia Research、Viral-associated cancers and disorders

Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for patients with progression within 12 months of first-line chemoimmunotherapy. In patients with late relapse, platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue is recommended. In second relapse, CAR T-cell or CD3xCD20 bispecific antibody therapy is recommended in eligible patients. Other treatment options are available for less fit patients. Specific recommendations are made on diagnostic immunohistochemistry, bendamustine use and bridging to CAR T-cell therapy.